MedPath

TriVascular Post-Market Registry

Completed
Conditions
Abdominal Aortic Aneurysm
Interventions
Device: Ovation™ or Ovation Prime™ Abdominal Stent Graft System
Registration Number
NCT01372709
Lead Sponsor
TriVascular, Inc.
Brief Summary

This is a prospective observational post-market study of subjects receiving the Ovation™ or Ovation Prime™ Abdominal Stent Graft System ("Ovation™ or Ovation Prime™ Abdominal Stent Graft System Post-Market Study") in the treatment of abdominal aortic aneurysms (AAA). The Ovation™ or Ovation Prime™ Abdominal Stent Graft System Post-Market study is intended to expand the clinical knowledge base by collecting data on subjects treated with the Ovation™ or Ovation Prime™ Abdominal Stent Graft System in actual clinical practice following commercial approval.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
501
Inclusion Criteria
  • Subject is > 18 years or minimum age as required by local regulations.
  • Indication for elective repair of AAA with an endovascular stent graft in accordance with the Instructions for Use of the Ovation™ or Ovation Prime™ Abdominal Stent Graft System.
  • Subject has signed an Ethics Committee (EC) approved Informed Consent Form. The subject or legal representative has been informed of the nature of the study, has consented to participate, and has authorized the collection and release of his/her medical information.
  • Subject intends to electively receive the Ovation™ or Ovation Prime™ Abdominal Stent Graft System.
  • Subject has the ability and willingness to comply with all follow-up exams as indicated in clinical investigation plan.
Exclusion Criteria
  • Subject demonstrates high probability of non-adherence to physician's follow-up requirements.
  • Subject's current participation in a concurrent randomized control trial (RCT) or investigational device/drug study which could confound study results.
  • Life expectancy less than 1 year
  • Pregnancy
  • Subjects with poor renal function as indicated by a serum creatinine > 2.5mg/dl.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Ovation™ or Ovation Prime™ Abdominal Stent Graft SystemOvation™ or Ovation Prime™ Abdominal Stent Graft SystemAdult male and female patients will be consecutively screened for the study. Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.
Primary Outcome Measures
NameTimeMethod
Treatment Success at 12 Months Post-Implantation/surgery.12 Months

The primary endpoint is treatment success at 12 months post-implantation/surgery. Treatment success is defined as a composite technical endpoint composed of successful introduction and deployment of the Ovation™ or Ovation Prime™ Abdominal Stent Graft System at the initial implantation procedure along with clinical endpoints of absence from type I or III endoleaks, aneurysm expansion, aneurysm rupture, conversion to open surgical repair, graft migration, and graft occlusion at 12 months post-implantation procedure.

Secondary Outcome Measures
NameTimeMethod
Safety and Performance Endpoints1, 6, &12 Months

* Freedom from type I and III endoleaks \[1 \& 6 m, \& annual through 5 years\]

* Freedom from aneurysm rupture \[6 m, \& annual through 5 years\]

* Freedom from aneurysm related mortality \[1 month\]

* Freedom from aneurysm expansion \[6 m, \& annual through 5 years\]

* Freedom from stent graft migration \[6 m, \& annual through 5 years\]

* Freedom from loss of device patency \[1 \& 6 m, \& annual through 5 years\]

* Freedom from aneurysm-related secondary endovascular procedures \[1 \& 6 m, \& annual through 5 years\]

* Freedom from device related adverse events \[1 \& 6 m, \& annual through 5 years\]

Trial Locations

Locations (30)

Imelda Ziekenhuis

🇧🇪

Bonheiden, Belgium

Ospedale San Raffaele

🇮🇹

Milan, Italy

Università La Sapienza/Policlinico Umberto I

🇮🇹

Roma, Italy

St. George's Vascular Institute

🇬🇧

London, United Kingdom

Medical University of Vienna Dept. for Radiology, Section for Cardiovascular and Interventional Radiology

🇦🇹

Wien, Austria

O.L. Vrouwziekenhuis

🇧🇪

Aalst, Belgium

Flanders Medical Research Program

🇧🇪

Dendermonde, Belgium

Universiteit Gent

🇧🇪

Gent, Belgium

UZ Leuven

🇧🇪

Leuven, Belgium

Groupe Hospitalier Edouard Herriot

🇫🇷

Lyon, France

Hôpital Paul d'Egine

🇫🇷

Paris, France

Herz- und Gefässzentrum Bad Bevensen

🇩🇪

Bad Bevensen, Germany

Park Hospital Leipzig, Strümpellstr. 41

🇩🇪

Leipzig, Western Saxony Land, Germany

Universitäres Herz und Gefaßzentrum Hamburg

🇩🇪

Hamburg, Germany

Franziskus-Krankenhaus Berlin

🇩🇪

Berlin, Germany

Cardiovascular Center

🇩🇪

Frankfurt, Germany

Städtisches klinikum Karlsruhe Klinik für Gefäß- und Thoraxchirurgie

🇩🇪

Karlsruhe, Germany

"CA Gefäßchirurgie Theresienkrankenhaus/St. Hedwig"

🇩🇪

Mannheim, Germany

Attikon Hospital

🇬🇷

Athens, Greece

Policlinico San Donato

🇮🇹

Milan, Italy

Ospedale Civico Palermo

🇮🇹

Palermo, Italy

Ospedale Bianchi Melacrino Morelli

🇮🇹

Reggio Calabria, Italy

Azienda Ospedaliera Sant'Andrea

🇮🇹

Roma, Italy

Ospedale San Giovanni Addolorata

🇮🇹

Roma, Italy

Univeristà La Sapienza/Policlinico Umberto I

🇮🇹

Rome, Italy

Södersjukhuset

🇸🇪

Stockholm, Sweden

Ospedale San Giovanni Bosco

🇮🇹

Torino, Italy

A.O. Ospedale di Circolo e Fondazione Macchi

🇮🇹

Varese, Italy

Frimley Park Hospital NHS Foundation Trust

🇬🇧

Frimley, United Kingdom

Manchester Royal Infirmary

🇬🇧

Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath